All members reviewed the final draft.<h4>Key findings</h4>The committee commented on recommendations with nuance for Canadian practitioners, especially on multidisciplinary care, challenges with genetic testing, and the use of CKD therapies like sodium-glucose transport protein 2 (SGLT2) inhibitors in ADPKD.<h4>Limitations</h4>The committee relied on the evidence summaries produced by KDIGO and the experience and knowledge of committee members. The gene discussed is SLC5A2; the disease is chronic kidney disease.